6-(2,3-Dichlorophenyl)-1,2,4-Triazine-3,5-Diamine 6-(2,3-二氯苯基)-1,2,4-三嗪-3,5-二胺
CAS 84057-84-1 MFCD00865333
化学结构图
SMILES: Nc1nnc(-c2cccc(Cl)c2Cl)[13c](N)n1
化学属性
| Mol. Formula | C9H7Cl2N5 |
|---|---|
| Mol. Weight | 256.09 |
| Melting Point | 216-220 |
别名和识别编码
| Chemical Name | 6-(2,3-Dichlorophenyl)-1,2,4-Triazine-3,5-Diamine |
|---|---|
| Synonym | 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine, 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine GI 267119X BW 430C GI 267119X Lamictal Lamotrigine |
| PubChem Substance ID | 160871245 |
| EC Number | 281-901-8 |
| MDL Number | MFCD00865333 |
| Chemical Name Translation | 6-(2,3-二氯苯基)-1,2,4-三嗪-3,5-二胺 |
| Beilstein Registry Number | 7589268 |
| CAS Number | 84057-84-1 |
| LabNetwork Molecule ID | LN00193340 |
| Reaxys-RN | 7589268 |
| Merck Number | 5353 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- {SNA} Anticonvulsants, Approved Therapeutics/Drug Candidates, Bioactive Small Molecules, Cell Biology, Cell Signaling and Neuroscience, GlaxoSmithKline, L, Neurobiology, Neuroscience, Pharmacologicals
- {SNA} Anticonvulsants, Approved Therapeutics/Drug Candidates, Bioactive Small Molecule Alphabetical Ind
安全信息
GHS Symbol
- H301 Toxic if swallowed 吞食有毒
- P264 Wash hands thoroughly after handling. 处理后要彻底洗净双手。
- P270 Do not eat, drink or smoke when using this product. 使用本产品时不要吃东西，喝水或吸烟。
- P301+P310
- P301+P310+P330
- P405 Store locked up. 上锁保管。
- P501 Dispose of contents/container to..… 处理内容物/容器.....
- S45 In case of accident or if you feel unwell seek medical advice immediately (show the label where possible) 发生事故时或感觉不适时，立即求医（可能时出示标签）；
- R25 Toxic if swallowed 吞咽有毒
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - man DOSE/DURATION : 19 mg/kg TOXIC EFFECTS : Behavioral - muscle contraction or spasticity Sense Organs and Special Senses (Eye) - effect, not otherwise specified Cardiac - EKG changes not diagnostic of specified effects REFERENCE : LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 342,1552,1993
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 245 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : EPILAK Epilepsia (New York). (Raven Press, 1185 Ave. of the Americas, New York, NY 10036) Ser.1-3: 1909-55; Ser.4: V.1- 1959- Volume(issue)/page/year: 25,655,1984
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 205 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : EPILAK Epilepsia (New York). (Raven Press, 1185 Ave. of the Americas, New York, NY 10036) Ser.1-3: 1909-55; Ser.4: V.1- 1959- Volume(issue)/page/year: 25,655,1984
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 2 mg/kg/30H-I TOXIC EFFECTS : Gastrointestinal - nausea or vomiting Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) REFERENCE : PEDIAU Pediatrics. (American Academy of Pediatrics, P.O. Box 1034, Evanston, IL 60204) V.1- 1948- Volume(issue)/page/year: 98,294,1996
京ICP备2020036287号